The gene therapy market is estimated to be worth USD 14.6 billion in 2030, predicts {Roots Analysis}

 

Given their potential to treat rare, inherited diseases, as well as those previously deemed incurable, the field of gene therapy has gained significant traction in the last few years

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (4th Edition), 2020-2030”.

 

The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, immunotherapies and gene editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. In addition to other elements, the study includes:

§  A detailed review of the overall market landscape of gene therapies and gene editing therapies, including information on phase of development of pipeline candidates, key therapeutic areas, target disease indication(s), type of vector used, type of gene, type of modification, type of gene therapy, route of administration and special drug designation(s) awarded (if any).

§  A detailed review of the players engaged in the development of gene therapies.

§  An elaborate discussion on the various types of viral and non-viral vectors.

§  A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America, Europe and Asia-Pacific.

§  Detailed profiles of marketed and late stage (phase II/III and above) gene therapies.

§  An elaborate discussion on the various commercialization strategies that can be adopted by drug developers across different stages of therapy development.

§  A review of the various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies.

§  An in-depth analysis of various patents that have been filed / granted related to gene therapies and gene editing therapies, since 2016.

§  A detailed analysis of the various mergers and acquisitions that have taken place within this domain, during the period 2015-2020.

§  An analysis of the investments made at various stages of development in companies that are focused in this area, between 2015-2020.

§  A detailed geographical clinical trial analysis of completed, ongoing and planned studies of numerous gene therapies.

§  An analysis of the various factors that are likely to influence the pricing of gene therapies.

§  An analysis of the big biopharma players engaged in this domain.

§  An informed estimate of the annual demand for gene therapies.

§  A case study on the prevalent and emerging trends related to vector manufacturing.

§  A discussion on the various operating models adopted by gene therapy developers for supply chain management.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  • Therapeutic Approach 

§  Gene augmentation

§  Oncolytic therapy

§  Immunotherapy

§  Others

  • Type of gene therapy

§  Ex vivo

§  In vivo

  • Type of vector used

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Others

  • Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Dermatological disorders

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Muscle-related diseases

§  Oncological disorders

§  Ophthalmic diseases

§  Others

  • Route of administration

§  Intraarticular

§  Intracerebellar

§  Intradermal

§  Intramuscular

§  Intratumoral

§  Intravenous

§  Intravesical

§  Intravitreal

§  Subretinal

§  Others

  • Key geographical regions 

§  North America

§  Europe

§  Asia-Pacific

 

Key companies covered in the report

§  Abeona Therapeutics

§  Advantagene

§  Biogen

§  bluebird bio

§  Castle Creek Biosciences

§  CG Oncology

§  FerGene

§  Freeline Therapeutics

§  Gradalis

§  Helixmith

§  Inovio Pharmaceuticals

§  Kolon TissueGene

§  Krystal Biotech

§  Lysogene

§  Neurophth Therapeutics

§  OncoSec Immunotherapies

§  Orchard Therapeutics

§  Pfizer

§  Sangamo Therapeutics

§  Spark Therapeutics

§  uniQure Biopharma

§  VBL Therapeutics

 

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

Other Recent Offerings

1.       Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition), 2021-2030

2.       Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030

3.       Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more